Vistagen receives EPO notice of intention to grant AV-101 patent for neuropathic pain

Vistagen Therapeutics, Inc.

European Patent Office issued Notice of Intention to Grant patent for AV-101 to treat neuropathic pain.
Patent will not expire until at least 2034; adds to global AV-101 portfolio.
Preclinical data show AV-101 similar efficacy to gabapentin and pregabalin with better side effect profile.
Phase 1 data demonstrate AV-101 well-tolerated with no meaningful difference vs placebo.
Vistagen plans to seek strategic collaborations to advance AV-101 development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.